RESUMO
Background: We aimed to characterise the adaptive immune response to Mycobacterium abscessus complex (MABSC) and its cross-reactivity with Mycobacterium avium complex (MAC) and Mycobacterium bovis (Bacille Calmette-Guérin, BCG) in cystic fibrosis (CF) patients and non-CF controls in terms of lymphocyte proliferation and immunophenotyping, cytokine production and anti-MABSC IgG plasma levels. Methods: In this cross-sectional analysis, peripheral blood mononuclear cells (PBMC) from CF patients with MABSC (CF/MABSC, n=12), MAC infection history (CF/MAC, n=5), no NTM history (CF/NTM-, n=15), BCG-vaccinated (C/BCG+, n=9) and non-vaccinated controls (C/BCG-, n=8) were cultured for four days under stimulation with an in-house MABSC lysate and we used flow cytometry to assess lymphocyte proliferation (given by lymphoblast formation) and immunophenotypes. Cytokine production was assessed after overnight whole blood stimulation with the same lysate, and anti-MABSC IgG levels were measured in plasma from non-stimulated blood. Results: All CF/MABSC patients had increased CD3+ and CD19+ lymphoblast formation upon PBMC stimulation with MABSC lysate. There was a higher rate of CD3+ than CD19+ lymphoblasts, predominance of CD4+ over CD8+ lymphoblasts, IFN-γ, TNF-α and IL-2 production, low production of the Th17-associated IL-17, and discrete or no production of Th2/B cell-associated cytokines soluble CD40 ligand (CD40L), IL-4 and IL-5, indicating a Th1-dominated phenotype and infection restricted to the lungs. A similar pattern was seen in C/BCG+ controls, and CF/MAC patients, pointing to cross-reactivity. MABSC-IgG levels were higher in CF/MABSC patients than in both control groups, but not CF/NTM- patients, most of whom also had CD3+ and/or CD19+ lymphoblast formation upon PBMC stimulation, indicating previous exposure, subclinical or latent infection with MABSC or other NTM. Conclusion: The anti-MABSC immune response is Th1-skewed and underlines the cross-reactivity in the anti-mycobacterial immune response. The results, together with published clinical observations, indicate that BCG vaccination may cross-react against NTM in CF patients, and this should be investigated. Due to cross-reactivity, it would also be interesting to investigate whether a combination of MABSC-induced cytokine production by blood cells and anti-MABSC IgG measurement can be useful for identifying latent or subclinical infection both with MABSC and other NTM in CF patients.
Assuntos
Fibrose Cística , Infecções por Mycobacterium não Tuberculosas , Mycobacterium abscessus , Imunidade Adaptativa , Vacina BCG , Estudos Transversais , Fibrose Cística/microbiologia , Citocinas , Humanos , Imunoglobulina G , Leucócitos Mononucleares , Infecções por Mycobacterium não Tuberculosas/microbiologiaRESUMO
The search for epitopes that will effectively trigger an immune response remains the "El Dorado" for immunologists. The development of promising immunotherapeutic approaches requires the appropriate targets to elicit a proper immune response. Considering the high degree of HLA/TCR diversity, as well as the heterogeneity of viral and tumor proteins, this number will invariably be higher than ideal to test. It is known that the recognition of a peptide-MHC (pMHC) by the T-cell receptor is performed entirely in a structural fashion, where the atomic interactions of both structures, pMHC and TCR, dictate the fate of the process. However, epitopes with a similar composition of amino acids can produce dissimilar surfaces. Conversely, sequences with no conspicuous similarities can exhibit similar TCR interaction surfaces. In the last decade, our group developed a database and in silico structural methods to extract molecular fingerprints that trigger T-cell immune responses, mainly referring to physicochemical similarities, which could explain the immunogenic differences presented by different pMHC-I complexes. Here, we propose an immunoinformatic approach that considers a structural level of information, combined with an experimental technology that simulates the presentation of epitopes for a T cell, to improve vaccine production and immunotherapy efficacy.
Assuntos
Imunoterapia , Complexo Principal de Histocompatibilidade/imunologia , Peptídeos/química , Linfócitos T/imunologia , Vacinas Virais/imunologia , Animais , Epitopos/imunologia , Humanos , Peptídeos/imunologia , Receptores de Antígenos de Linfócitos T/imunologia , Reprodutibilidade dos TestesRESUMO
A cromoblastomicose é uma micose crônica que causa lesões granulomatosas e supurativas que atingem a pele e o tecido subcutâneo. Micose cosmopolita e freqüentemente observada no Brasil. As lesões aumentam progressivamente e posteriormente podem desenvolver um processo crônico e que geralmente não respondem a uma terapia convencional. Entretanto o mecanismo de defesa da resposta imune adaptativa, principalmente das células T na cromoblastomicose ainda não está definido. Em nosso estudo avaliamos a produção de citocinas e a resposta linfoproliferativa de diferentes amostras de sangue de pacientes com cromoblastomicose e indivíduos saudáveis in vitro após estimulação com antígenos do fungo. Além disso, nos acompanhamos esses pacientes sob terapia antifúngica em diferentes períodos de tratamento. Este estudo mostrou que a forma grave da cromoblastomicose é caracterizada pelo aumento na produção de IL-10 e deficiência na proliferação das células T após estimulação com antígenos do fungo. Ao contrario, pacientes com a forma leve da doença foram capazes de secretar predominantemente IFN-γ, que é uma citocina importante para defesa do hospedeiro. Em adição eles secretaram menores quantidades de IL-10 e suas células T proliferaram eficientemente in vitro após estimulação do fungo. Os pacientes avaliados após 6 meses de terapia antifúngica as células T proliferaram e secretaram altos níveis de IFN-γ eficientemente após estimulação. Ao contrário, pacientes com 12 meses de tratamento ocorreu um aumento na produção de IL-10 uma diminuição nos níveis de linfoproliferação. Interessantemente, os monócitos obtidos desses pacientes durante a doença foram capazes expressar moléculas co-estimulatorias (CD80 e CD86) e também aumento nos níveis de HLA-DR após estimulação com LPS. Além disso, monócitos desses pacientes secretam altos níveis de IL-12 e TNF-α, sugerindo que a suscetibilidade desses pacientes não apresentam uma deficiência na apresentação de antígeno por monócitos. Em suma, em nossos resultados mostraram que alta secreção de IFN-γ e eficiente proliferação de células T de pacientes com cromoblastomicose está diretamente relacionada com a forma leve da doença, enquanto que a produção de IL-10 e diminuição na proliferação de células T caracterizam a forma grave da doença
Chromoblastomycosis is a chronic granulomatous and suppurative disease that causes lesions mainly in skin and subcutaneous tissues. Although found worldwide, this mycosis is frequently observed in tropical countries such as Brazil. The skin lesions increase slowly and progressively in a chronic process that usually relapse even after canonical treatment. However, the mechanism of the host adaptive immune response, specially the role of T cells, in chromoblastomycosis is still unclear. In studies here, we evaluated the cytokine production and T cell response of peripheral blood mononuclear cells (PBMC) from different patients and healthy controls upon in vitro stimulation with fungal antigens. Moreover, we performed a follow-up study in patients undergoing long-term antifungal treatment. We collected PBMC samples from patients with an active form (either severe or mild skin lesions) of chromoblastomycosis and PBMC samples from healthy individuais. In PBMC from patients with a severe form of the disease we found a predominant production of IL-10 over IFN-gamma and a deficiency in T cell proliferation upon fungal antigen stimulation. In contrast, PBMC from patients in a mild form of the disease were able to secrete predominantly IFN-gamma, a cytokine important for host defense. In addition, they secreted low amounts of IL-10 and their T cells efficiently proliferated under in vitro stimulation with the fungal antigens. Surprisingly, the patients undergoing 6 months antifungal therapy PBMC from patients secreted higher amounts of IFN-gamma and their T cells proliferated efficiently upon stimulation. On the contrary, PBMC from patients after 12m of treatment showed an increase in IL-10 secretion followed by an inefficient T cell proliferation. Interestingly, monocytes obtained from patients during chronic phase of the disease were able to up-regulate their co-stimulatory molecules (CD80 and CD86) as well as their HLA-DR upon in vitro fungal stimulation. Moreover, monocytes from these patients secreted high amounts of pro-inflammatory cytokines IL-12 and TNF-alfa, suggesting that susceptibility of patients must be due to a immune deficiency other than a monocyte deactivation. Altogether, our data clearly show that a higher secretion of IFN-gamma and an efficient T cell proliferation of PBMC from infected individuals can distinguish the mild from the severe form of the chromoblastomycosis